Pulmonx (LUNG) Expected to Announce Earnings on Wednesday

Pulmonx (NASDAQ:LUNG) is expected to release its Q4 2025 results before the market opens on Wednesday, February 18th. Analysts expect the company to announce earnings of ($0.39) per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, February 18, 2026 at 4:00 PM ET.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06. Pulmonx had a negative return on equity of 77.58% and a negative net margin of 61.91%.The firm had revenue of $21.50 million for the quarter, compared to analyst estimates of $20.78 million. On average, analysts expect Pulmonx to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pulmonx Stock Performance

NASDAQ:LUNG opened at $1.45 on Wednesday. The firm’s fifty day simple moving average is $2.04 and its 200-day simple moving average is $1.83. The company has a quick ratio of 4.15, a current ratio of 4.86 and a debt-to-equity ratio of 0.62. The stock has a market cap of $59.81 million, a PE ratio of -1.03 and a beta of 0.07. Pulmonx has a fifty-two week low of $1.31 and a fifty-two week high of $9.37.

Wall Street Analyst Weigh In

LUNG has been the topic of several recent analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Pulmonx in a research report on Thursday, January 22nd. Lake Street Capital decreased their price target on Pulmonx from $8.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, October 28th. D. Boral Capital reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Pulmonx in a research note on Thursday, November 13th. Finally, Wall Street Zen raised Pulmonx from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. Five investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Pulmonx presently has an average rating of “Hold” and an average price target of $6.81.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd acquired a new stake in shares of Pulmonx during the 2nd quarter worth about $149,000. Norges Bank acquired a new position in shares of Pulmonx in the second quarter valued at approximately $392,000. Jane Street Group LLC lifted its stake in shares of Pulmonx by 3,328.7% during the second quarter. Jane Street Group LLC now owns 88,631 shares of the company’s stock valued at $230,000 after buying an additional 86,046 shares during the period. Bank of America Corp DE boosted its position in Pulmonx by 556.6% during the second quarter. Bank of America Corp DE now owns 481,268 shares of the company’s stock worth $1,246,000 after acquiring an additional 407,971 shares during the last quarter. Finally, Two Sigma Investments LP boosted its position in Pulmonx by 50.3% during the third quarter. Two Sigma Investments LP now owns 46,456 shares of the company’s stock worth $75,000 after acquiring an additional 15,557 shares during the last quarter. Institutional investors and hedge funds own 91.04% of the company’s stock.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.